Skip to main content
ENDO 2026 Main banner

Diabetes and Vascular Disease

SAT-547 - Akkermansia muciniphila Supplementation on Insulin Resistance and Glycemic Control: A Systematic Review of Randomized Controlled Trials

Saturday, June 13, 2026
9:30 AM - 4:30 PM CT
Insulin resistance is one of the main pathophysiological mechanisms involved in the development of type 2 diabetes mellitus and other metabolic disorders, highlighting the need for effective therapeutic strategies for its prevention and control. In this context, the gut microbiota has emerged as an important modulator of glycemic homeostasis, especially Akkermansia muciniphila, a gram-negative anaerobic bacterium that resides in the intestinal mucus layer. Recent studies have associated supplementation with this microorganism with metabolic benefits, including improved insulin sensitivity and glycemic control. Therefore, this systematic review aimed to evaluate the effects of Akkermansia muciniphilasupplementation on insulin resistance and glycemic control in individuals with metabolic disorders.
A qualitative systematic review was conducted according to PRISMA guidelines using PubMed, Embase, and Cochrane Library databases. Observational studies and clinical trials evaluating individuals with insulin resistance and/or glycemic disorders who received Akkermansia muciniphila supplementation were included. A total of 368 studies were identified and screened through a double-blind selection process by the authors, resulting in 2 eligible studies for analysis. Basic descriptive statistics were performed to assess improvements in insulin resistance and glycemic control.
The qualitative analysis suggests that Akkermansia muciniphila supplementation is safe and associated with metabolic improvement. Zhang et al. (2025) demonstrated that the efficacy of the live strain depends on baseline intestinal abundance, with improvements in body weight, fat mass, and HbA1c observed only in individuals with low initial abundance, while high baseline levels may lead to competitive exclusion. Depommier et al. (2019) showed that pasteurized A. muciniphila was superior to the live strain, significantly improving insulin sensitivity (+28.62 ± 7.02%, P = 0.002), reducing insulinemia (-34.08 ± 7.12%, P = 0.006), and lowering total plasma cholesterol (-8.68 ± 2.38%, P = 0.02), as well as hepatic markers such as GGT and AST.
In conclusion, Akkermansia muciniphila supplementation appears to be a safe and promising intervention for improving insulin resistance and metabolic parameters in individuals with glycemic disorders. Pasteurized formulations may provide more consistent benefits than live strains, and treatment efficacy seems to depend on the individual’s baseline microbiota composition. These findings support the potential need for prior microbiome testing to optimize therapeutic outcomes. However, further studies are required to better define its clinical applicability and establish individualized treatment strategies.

*Unless otherwise noted, all abstracts presented at ENDO must not be released to the press or the public until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.*